CMS Releases CY27 MA and Part D Policy and Technical Changes Final Rule

CMS issued the CY2027 Medicare Advantage and Part D final rule on April 2, finalizing STAR rating changes (removing the Excellent Health Outcomes for All reward and 11 administrative measures) and implementing Inflation Reduction Act-driven Part D changes that eliminate the coverage gap phase, reduce the annual out-of-pocket threshold, and remove enrollee cost-sharing in the catastrophic phase. The rule also removes the MA requirement to send mid-year notices about unused supplemental benefits and rolls back certain MA health-equity requirements; CMS said comments will be considered in future rulemaking. These policy shifts are material for MA plans, Part D sponsors, PBMs and pharmaceutical manufacturers—likely reducing revenues/margins for plans and drug makers while improving beneficiary out-of-pocket exposure.

Analysis

The recent CMS action creates a durable re-pricing event for the Medicare value chain that will play out unevenly over 6–24 months as rate filings, formularies and utilization controls are reworked. Large vertically-integrated players with PBMs and diversified commercial lines can monetize administrative and care-management levers (prior auth, step edits, network steering) faster than smaller pure-play MA carriers that must take near-term medical-loss volatility to shareholders. Specialty drug manufacturers face a complex mix: faster volume growth from lower patient cost barriers but higher negotiation pressure and uncertainty around net pricing evolution — that dynamic favors manufacturers with scale in specialty distribution and those able to accelerate price realization pre-implementation.

Expect near-term margin pressure to be concentrated in the next 2–3 quarters of rate resets and guidance cycles; however, plans retain substantive behavioral levers that can claw back much of the projected spend within 12–18 months (narrow networks, benefit carve-outs, aggressive utilization management). Regulatory/political risk is asymmetric: congressional or CMS corrective action could materially reverse industry assumptions but would likely take 9–18 months. The sector bifurcates into businesses that can flex administrative revenue and those that cannot — that dichotomy creates clear tradeable opportunities across insurers, PBMs and smaller MA operators.

Key Decisions for Investors

• Long UNH (UnitedHealth) 6–18 month horizon — thesis: integrated PBM + broad commercial book can offset MA churn via administrative revenue and care-management savings. Target total return 20–40% vs downside 15–20% if regulatory tightening hits; size as core overweight.
• Long CVS 6–12 months (CVS Health) — play PBM / retail pharmacy optionality to capture gross-to-net and drive adherence-led pharmacy flows. Use 9–12 month calls ~5–10% OTM if looking for asymmetric payoff; expect 25–50% upside if utilization management and pharmacy margins hold.
• Pair trade: long UNH / short CNC (Centene) over 9–15 months — rationale: UNH can flex PBM and commercial rate actions, CNC is more exposed to government programs and has less capacity to offset medical-loss pressure. Target 2:1 risk-reward — pair expected to outperform if coasted repricing unfolds as modeled.
• Short MOH (Molina) as a hedge or standalone 3–12 month trade — smaller MA/Medicaid-focused operators are most exposed to acute hit in Medicare flows and have limited PBM offset. Risk: sector relief or premium increases could blunt losses; cap position size accordingly.